Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03671018
Title A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate

Bendamustine + Polatuzumab vedotin-piiq + Rituximab

Bendamustine + Obinutuzumab

Mosunetuzumab + Polatuzumab vedotin-piiq

Mosunetuzumab

Obinutuzumab

Tocilizumab

Age Groups: adult | senior
Covered Countries USA | ESP | CAN | BEL


No variant requirements are available.